Area of Research: PARP Inhibitors

2021 Grant Recipients

• Sridevi Challa, PhD, UT Southwestern Medical Center
  Ann and Sol Schreiber Mentored Investigator Award
  Role of Ribosomal Protein Mono(ADP-ribosyl)ation in Protein Quality Control
• Benoît Bragantini, PhD, Mayo Clinic
  Ann and Sol Schreiber Mentored Investigator Award
  Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM
• Ichiko Kinjyo, MD, PhD, University of New Mexico
  Liz Tilberis Early Career Award
  A Novel Mechanism for the Immunomodulatory Effects of PARP-inhibitor
• Arun Kanakkanthara, PhD, Mayo Clinic
  Liz Tilberis Early Career Award
  Exploiting a Metabolic Dependency of PARPinhibitor-Resistant Ovarian Cancer
• Liya Ding, PhD, Dana Farber Cancer Institute
  Liz Tilberis Early Career Award
  Targeting Therapeutic Resistance to PARP Inhibition in Ovarian Cancer
• Ivan Ahel, PhD, University of Oxford
  Collaborative Research Development Grant
  Exploiting PARP-Modulating Enzymes in Ovarian Cancer Therapy

2020 Grant Recipients

• Nidhi Sahni, PhD, MD Anderson Cancer Center
  Liz Tilberis Early Career Award
  Systems Approach for PARP-based Novel Combination Therapy in Ovarian Cancer
• Janice Santiago, PhD, MD Anderson Cancer Center
  Ann and Sol Schreiber Mentored Investigator Award
  Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer

2019 Grant Recipients

• Sarah Gitto, PhD, University of Pennsylvania
  Ann and Sol Schreiber Mentored Investigator Award
  Modeling Autologous TIL Therapy in Novel PARP Resistant PDX Model for Ovarian Cancer
• Marilyne Labrie, PhD, Oregon Health and Science University
  Ann and Sol Schreiber Mentored Investigator Award
  Synergistic Lethality of PARP and P13K Pathway Inhibitors in Ovarian Cancer
• Shariska Petersen, MD, University of Kansas Medical Center Research Institute
  Ann and Sol Schreiber Mentored Investigator Award
  Cyclin E and BRD4 as Markers for a New PARPi Drug Combination

2018 Grant Recipients

• Shih-Hsun Chen, PhD, Beckman Research Institute of the City of Hope
  Ann and Sol Schreiber Mentored Investigator Award
  Targeting de-poly (ADP-ribosyl)ation for Ovarian Cancer Therapy
• Maria Victoria Botuyan, PhD, Mayo Clinic
  Liz Tilberis Early Career Award
  Probing the Antagonistic Roles of 53BP1 and RAD18 in HR DNA Repair
• Jian Yuan, PhD, Mayo Clinic
  Liz Tilberis Early Career Award
  The Role of BRD9-Rad51 Axis in Chemoresistance in Ovarian Cancer

2017 Grant Recipients

• Anniina Farkkila, MD, PhD, Dana Farber Cancer Institute
  Ann and Sol Schreiber Mentored Investigator Award
  Overcoming PARP Inhibitor Resistance in Ovarian Cancer

2015 Grant Recipients

• Sarah Adams, MD, University of New Mexico
  Liz Tilberis Early Career Award
  A Combination Therapy for Hereditary Ovarian Cancer

2014 Grant Recipients

• Barbara Stulken Norquist, MD, University of Washington
  Liz Tilberis Early Career Award
  Molecular Biomarkers to Predict PARP Inhibitor Response in Ovarian Cancer
• Mo Li, PhD, University of Michigan
  Ann and Sol Schreiber Mentored Investigator Award
  Mechanism of PARP Inhibitor in Ovarian Cancer Therapy Cancer

2013 Grant Recipients

• Elizabeth Swisher, MD, University of Washington
  Collaborative Research Development Grant
  The FA-BRCA Pathway and Response to Platinum and PARP Inhibitors in Ovarian, Tubal and Peritoneal Carcinomas

2012 Grant Recipients

• See-Hyoung Park, PhD, Stanford University
  Ann and Sol Schreiber Mentored Investigator Award
  Targeting Ovarian Cancer with Combination of Olaparib and Bepridil

2011 Grant Recipients

• Sarah Adams, MD, University of Pennsylvania
  Liz Tilberis Early Career Award
  Development of Combination Therapy with PARP-Inhibitors and Immunomodulation for BRCA1-Epithelial Ovarian Cancer

2008 Grant Recipients

• Lejla Delic, MD, Cedars-Sinai Medical Center
  Ann and Sol Schreiber Mentored Investigator Award
  A New Class of Drugs with Potential Against Ovarian Cancer: PARP-inhibitors